Show Me the Data™: HER2-Mutant NSCLC in Transition — Translating Evidence to Practice

Overview:

HER2-mutant NSCLC is undergoing rapid transformation as new HER2-directed therapies, including next-generation tyrosine kinase inhibitors and antibody-drug conjugates, move into earlier lines of treatment. Clinicians face ongoing challenges related to optimal biomarker testing, interpretation of emerging efficacy and safety data across HER2 mutation subtypes, selection of frontline therapy, sequencing after progression, and management of treatment-related toxicities.

This 90-minute hybrid Show Me the Data™ satellite symposium, presented adjunct to the 2026 ESMO Congress in Madrid, will use case-based discussions, audience polling, focused data presentations, and expert panel discussion. The program will help clinicians translate emerging HER2-directed evidence into practical treatment strategies for patients with HER2-mutant NSCLC.

Learning Objectives:

Upon completion of this activity, participants will be able to:

• Identify current best practices for HER2 biomarker testing in NSCLC, including assay selection, timing, and integration into clinical workflows.
• Evaluate recent and emerging clinical trial data supporting the use of HER2-directed therapies in HER2-mutant NSCLC.
• Develop personalized treatment strategies for patients with HER2-mutant NSCLC, incorporating evidence-based sequencing decisions, management of intracranial disease, and proactive mitigation of treatment-related toxicities

Target Audience:

This educational activity is directed toward oncologists, advanced practice providers, nurses, pharmacists, and other HCPs involved in the diagnosis and treatment of NSCLC.

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.